AGS-16M8F

Astellas Pharma Inc · Phase 1 active Small molecule

At a glance

Generic name	AGS-16M8F
Sponsor	Astellas Pharma Inc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AGS-16M8F CI brief — competitive landscape report
AGS-16M8F updates RSS · CI watch RSS
Astellas Pharma Inc portfolio CI